Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2017 1
2019 1
2020 8
2021 8
2022 9
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hanaki nakajima (23 results)?
Brazilian green propolis improves gut microbiota dysbiosis and protects against sarcopenic obesity.
Okamura T, Hamaguchi M, Bamba R, Nakajima H, Yoshimura Y, Kimura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Nishimoto Y, Yamada T, Fujikura C, Asama T, Okumura N, Takakuwa H, Sasano R, Fukui M. Okamura T, et al. Among authors: nakajima h. J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):3028-3047. doi: 10.1002/jcsm.13076. Epub 2022 Sep 26. J Cachexia Sarcopenia Muscle. 2022. PMID: 36162824 Free PMC article.
Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice.
Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, Kitagawa N, Hashimoto Y, Majima S, Senmaru T, Okada H, Ushigome E, Nakanishi N, Takakuwa H, Sasano R, Hamaguchi M, Fukui M. Hata S, et al. Among authors: nakajima h. Nutrients. 2022 Aug 27;14(17):3531. doi: 10.3390/nu14173531. Nutrients. 2022. PMID: 36079789 Free PMC article.
Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study.
Saijo Y, Okada H, Hata S, Nakajima H, Kitagawa N, Okamura T, Osaka T, Kitagawa N, Majima S, Senmaru T, Ushigome E, Nakanishi N, Hamaguchi M, Fukui M. Saijo Y, et al. Among authors: nakajima h. J Clin Med. 2023 Nov 9;12(22):6993. doi: 10.3390/jcm12226993. J Clin Med. 2023. PMID: 38002608 Free PMC article.
Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus.
Yoshimura Y, Hashimoto Y, Okada H, Takegami M, Nakajima H, Miyoshi T, Yoshimura T, Yamazaki M, Hamaguchi M, Fukui M. Yoshimura Y, et al. Among authors: nakajima h. J Diabetes Investig. 2023 Oct;14(10):1175-1182. doi: 10.1111/jdi.14054. Epub 2023 Jul 9. J Diabetes Investig. 2023. PMID: 37424302 Free PMC article. Clinical Trial.
Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study.
Hamaguchi M, Yoshimura Y, Nakajima H, Tanaka T, Hasegawa G, Ishii M, Okada H, Mitsuhashi K, Kitagawa N, Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Fukui M; RISING-STAR study group. Hamaguchi M, et al. Among authors: nakajima h. J Clin Biochem Nutr. 2022 Sep;71(2):158-164. doi: 10.3164/jcbn.22-7. Epub 2022 May 17. J Clin Biochem Nutr. 2022. PMID: 36213793 Free PMC article.
32 results